An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

LESSONS LEARNED. TKM‐080301 showed a favorable toxicity profile at the studied dose. TKM‐080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in patients with advanced hepatocellular carcinoma compared with historical control. Preliminary antitu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: El Dika, Imane, Lim, Ho Yeong, Yong, Wei Peng, Lin, Chia‐Chi, Yoon, Jung‐Hwan, Modiano, Manuel, Freilich, Bradley, Choi, Hye Jin, Chao, Tsu‐Yi, Kelley, Robin K., Brown, Joanne, Knox, Jennifer, Ryoo, Baek‐Yeol, Yau, Thomas, Abou‐Alfa, Ghassan K.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2018
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656521/
https://ncbi.nlm.nih.gov/pubmed/30598500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0838
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars